Executive Brief

News Report

The News: FDA approves elamipretide for Barth syndrome, the first treatment for this rare condition.
Clinical Win: This approval addresses a significant unmet need in pediatric patients with Barth syndrome.
Target Specialty: pediatrics, genetics, cardiology

Key Data at a Glance

Approval Date: September 19, 2025
Patient Population: Pediatric patients weighing at least 30 kg
Administration: Subcutaneous injection once daily
Common Side Effects: Mild-to-moderate injection site reactions

The FDA has granted accelerated approval for elamipretide (Forzinity) as the first treatment for Barth syndrome, a rare mitochondrial disorder, on September 19, 2025. This approval is significant for healthcare providers as it addresses a critical unmet need in pediatric patients weighing at least 30 kg, offering a potential improvement in muscle strength and overall quality of life.

Clinical Context

Barth syndrome is a rare genetic disorder primarily affecting males, characterized by cardiomyopathy, skeletal myopathy, and neutropenia. Patients often present with severe heart failure in infancy, leading to high morbidity and premature mortality. Those who survive into adolescence and adulthood frequently experience fatigue, poor stamina, and exercise intolerance, significantly impacting their daily activities and quality of life. Current treatment options are limited, focusing mainly on supportive care without addressing the underlying mitochondrial dysfunction. Elamipretide, a cardiolipin-targeting peptide, aims to enhance mitochondrial function and improve muscle strength, representing a novel approach in the management of Barth syndrome. The FDA's accelerated approval is based on promising data indicating that elamipretide may improve muscle strength, which is a critical aspect of managing this debilitating condition.

Key Findings

The FDA granted accelerated approval to elamipretide (Forzinity) for the treatment of Barth syndrome in patients weighing at least 30 kg based on its ability to improve muscle strength.

The approval is based on data from a randomized, double-blind, placebo-controlled trial that involved 12 male patients aged 12 years and older with genetically confirmed Barth syndrome [1].

The FDA requires a post-approval randomized, double-blind, placebo-controlled trial to confirm that the observed improvements in muscle strength translate into meaningful patient benefits, such as enhanced mobility and daily functioning.

Safety & Tolerability

Elamipretide is administered subcutaneously once daily, with common side effects including mild-to-moderate injection site reactions.
Clinicians should consult current prescribing information for full dosing guidance.

What This Means for Clinical Practice

Elamipretide provides a new therapeutic option for clinicians treating pediatric patients with Barth syndrome, addressing a significant gap in available therapies. This approval allows healthcare providers to offer a treatment that may improve muscle strength and potentially enhance the quality of life for affected patients. Clinicians should be aware of the ongoing requirement for post-marketing studies to validate the clinical benefits observed in trials. As this treatment becomes available, it will be essential to monitor patient responses and manage any adverse effects associated with elamipretide administration, ensuring comprehensive care for this vulnerable population.

Clinical Perspective

Workflow: Clinicians will need to integrate elamipretide into treatment plans for pediatric patients with Barth syndrome, focusing on monitoring muscle strength and mobility.

Economics: The introduction of elamipretide may lead to changes in healthcare resource allocation, particularly in specialized pediatric care settings.

Patient Outcomes: Improved muscle strength from elamipretide treatment could enhance the quality of life and daily functioning for patients with Barth syndrome.

Editorial Team, Rare Disease

References

FDA — FDA Grants Accelerated Approval to First Treatment for Barth Syndrome

FDA Approves Elamipretide for Barth Syndrome: First Treatment for Pediatric Patients

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Rare Disease in your inbox.

Related Drug Updates

FDA Approves Navepegritide for Achondroplasia: 1.5 cm Height Increase in Children

FDA Approves Tividenofusp Alfa for Hunter Syndrome: New Enzyme Replacement Therapy

FDA Reviews DTX401 Gene Therapy for GSDIa: GlucoGene Trial Results Expected in 2026

Verified HCP Portal